Core Viewpoint - Tivic Health® Systems, Inc. has announced a conference call to discuss the recent acquisition of CDMO assets, highlighting its strategic importance and potential benefits for the company [1] Group 1: Acquisition Details - The acquisition of certain CDMO assets was announced on December 11, 2025, and is expected to accelerate key strategic priorities for the company [1] - The conference call will address how this acquisition impacts development and commercialization timelines [1] Group 2: Future Prospects - The management will discuss near-term potential benefits resulting from the acquisition during the conference call [1]

Core Insights - Tivic Health® Systems, Inc. is advancing its strategic transformation and biologics pipeline, focusing on its lead product candidate, Entolimod, for acute radiation syndrome (ARS) [1] Financial Results - The company announced financial results for the third quarter and nine months ended September 30, 2025 [1] Business Update - Engagement with key government agencies has generated interest in Entolimod as a military medical countermeasure and stockpile drug [1]

Core Insights - Tivic Health Systems, Inc. has optimized key device and treatment parameters for ncVNS, enhancing its effectiveness through personalization [1] Company Developments - The company collaborated with The Feinstein Institutes for Medical Research at Northwell Health to conduct a study on ncVNS treatment [1] - Key parameters optimized include frequency, amplitude, electrode positioning, and duration of stimulation [1] Study Findings - Personalizing the frequency of ncVNS stimulation led to a 46% increase in heart rate variability, which was 8.9 times more effective than using a uniform frequency across all subjects [1] - The optimal ncVNS frequency varied between subjects and visits, highlighting the need for personalized stimulation parameters before each treatment [1] - Certain electrode placements and configurations were found to significantly impact heart rate variability, with some placements increasing it while others decreased it [1] - A duration of four minutes of ncVNS stimulation was sufficient to achieve a substantial increase in heart rate variability, proving more effective than twenty minutes of stimulation [1]